Lp(a): What This Test Actually Measures

What Lp(a) Is and Why It Differs From Standard LDL

Lipoprotein(a) is a low-density lipoprotein particle covalently bonded to apolipoprotein(a), a plasminogen-like glycoprotein. This structural addition makes Lp(a) both atherogenic and prothrombotic, a dual mechanism that standard LDL cholesterol cannot replicate.

The particle was first identified by Norwegian geneticist Kåre Berg in 1963. For decades it remained a research curiosity. That changed when genome-wide association studies confirmed that the LPA gene accounts for over 90% of the variance in circulating Lp(a) levels 1. Unlike LDL-C, triglycerides, or HDL-C, Lp(a) does not respond meaningfully to diet, exercise, or statin therapy. Statins may actually raise Lp(a) by 10-20%, though this finding has unclear clinical significance 2.

The particle carries oxidized phospholipids on its surface, which trigger inflammatory cascades within arterial walls. Its structural homology to plasminogen allows it to compete for plasminogen receptors, impairing fibrinolysis. This creates a prothrombotic state independent of other clotting factors.

A standard lipid panel does not isolate Lp(a). Your reported LDL-C number actually includes the cholesterol mass within Lp(a) particles. This means someone with a "normal" LDL-C of 110 mg/dL but an Lp(a) of 80 mg/dL has a genuinely different risk profile than someone with identical LDL-C but low Lp(a).

How the Lab Actually Measures Lp(a)

Most clinical laboratories use immunoturbidimetric or immunonephelometric assays that target the apolipoprotein(a) component. The test requires a venous blood draw. Fasting is not required because Lp(a) levels remain stable regardless of recent food intake 3.

Two reporting units exist, and they are not interchangeable through a simple mathematical conversion. Laboratories report Lp(a) in either mg/dL (measuring mass) or nmol/L (measuring molar concentration). The World Heart Federation and European Atherosclerosis Society (EAS) prefer nmol/L because mass-based assays are confounded by apolipoprotein(a) isoform size variability 4.

Apolipoprotein(a) contains repeating kringle IV type 2 (KIV-2) domains. The number of KIV-2 repeats varies between 2 and more than 40 copies. Small isoforms (fewer KIV-2 repeats) are associated with higher Lp(a) concentrations and appear to carry greater atherogenic potency per particle. Mass-based assays can underestimate or overestimate true particle number depending on isoform size.

The isoform-sensitivity problem is why the 2022 EAS consensus statement explicitly recommends that laboratories transition to isoform-insensitive assays calibrated against the WHO/IFCC reference material 4. If your lab reports in mg/dL, do not simply multiply by 2.5 to convert to nmol/L. That approximation fails at extreme isoform sizes.

Normal Ranges and Risk Thresholds

The distribution of Lp(a) across populations is heavily right-skewed. Most people have low levels, but approximately 1 in 5 adults worldwide carries a concentration above 50 mg/dL (125 nmol/L) 5.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias define the following thresholds:

• Desirable: <30 mg/dL (<75 nmol/L)
• Borderline: 30-50 mg/dL (75-125 nmol/L)
• Elevated: >50 mg/dL (>125 nmol/L)

The Canadian Cardiovascular Society uses a single cutpoint of 50 mg/dL to define high risk 6. The National Lipid Association similarly considers values above 50 mg/dL as warranting clinical attention.

Ethnicity affects baseline concentrations. Black individuals have median Lp(a) levels approximately two- to threefold higher than White individuals, a difference driven entirely by LPA gene variant frequencies rather than environmental factors 7. South Asian populations also carry disproportionately elevated levels, which may partly explain the excess cardiovascular burden observed in this group.

One critical point: Lp(a) remains remarkably stable from age 5 onward. A measurement taken at age 30 will reflect your level at age 60 with minimal drift. This stability underpins the "measure once" recommendation from the EAS.

Cardiovascular Risk: What Elevated Lp(a) Means Clinically

The Copenhagen General Population Study (N=69,764) demonstrated a continuous, log-linear relationship between Lp(a) concentration and myocardial infarction risk. Individuals with Lp(a) above the 95th percentile (approximately 180 mg/dL) had a 3- to 4-fold higher risk of MI compared to those below the 22nd percentile 8.

Dr. Børge Nordestgaard, the study's principal investigator, stated: "Elevated Lp(a) is present in one-fifth of the population and is associated with a two- to threefold increased risk of myocardial infarction and aortic valve stenosis. This makes it one of the most prevalent genetic risk factors for cardiovascular disease."

Beyond coronary disease, elevated Lp(a) independently predicts:

• Aortic valve calcific stenosis. Mendelian randomization studies show a causal relationship between LPA variants and aortic stenosis, with each 10 mg/dL increase in Lp(a) raising stenosis risk by approximately 10% 9.
• Ischemic stroke. A meta-analysis of 56,010 participants found that elevated Lp(a) conferred a 1.41-fold increase in stroke risk (95% CI 1.26-1.57) 10.
• Peripheral artery disease. The Atherosclerosis Risk in Communities (ARIC) study linked Lp(a) above 50 mg/dL to a 1.3-fold increase in PAD events.

The risk is not attenuated by standard statin therapy. A patient with Lp(a) of 70 mg/dL who achieves an LDL-C of 55 mg/dL on rosuvastatin still carries the residual cardiovascular risk imparted by elevated Lp(a).

Who Should Get Tested

The 2022 EAS Consensus Statement recommends measuring Lp(a) at least once in every adult's lifetime to identify those with very high inherited levels 4. The rationale: a single test identifies a lifelong risk factor at minimal cost (typically $30-80 out of pocket if not covered by insurance).

Priority testing populations include:

• Adults with premature atherosclerotic cardiovascular disease (ASCVD) before age 55 in men or 65 in women
• Individuals with a family history of premature ASCVD or elevated Lp(a)
• Patients with familial hypercholesterolemia
• Those with recurrent cardiovascular events despite optimal LDL-C control
• Patients with calcific aortic valve stenosis before age 75
• Individuals being risk-stratified for primary prevention whose 10-year ASCVD risk falls in a borderline or intermediate category

The 2018 AHA/ACC Multi-Society Cholesterol Guideline identifies Lp(a) ≥50 mg/dL as a "risk-enhancing factor" that can tip borderline-risk patients toward statin initiation 11. This makes the test directly actionable even before Lp(a)-specific therapies are available.

What Low Lp(a) Means

A low Lp(a) (below 10 mg/dL) carries no known adverse health consequences. It simply reflects a favorable genetic hand. No clinical action is required.

There is no such thing as "raising Lp(a)" for health benefit. The concept has no clinical basis. If a lab reports Lp(a) at 3 mg/dL, this is optimal.

Some conditions transiently lower Lp(a): acute phase response during illness, nephrotic syndrome (which elevates it acutely then may normalize), and hepatic dysfunction. These situational changes do not change the underlying genetic setpoint and will revert when the acute condition resolves.

Current and Emerging Treatments

No FDA-approved therapy exists specifically to lower Lp(a) as of May 2026. However, several approaches reduce levels to varying degrees, and three targeted therapies are in late-stage clinical trials.

Currently available agents with partial Lp(a) effects:

• PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by approximately 20-30% 12. The FOURIER trial (N=27,564) showed evolocumab reduced Lp(a) by a median of 26.9%.
• Niacin reduces Lp(a) by 20-30% but failed to demonstrate cardiovascular outcome benefit in the AIM-HIGH and HPS2-THRIVE trials.
• Lipoprotein apheresis removes Lp(a) acutely by 60-70% per session but requires biweekly treatments and is limited to specialized centers.

Pipeline therapies (Phase III):

• Pelacarsen (Novartis/Ionis): An antisense oligonucleotide targeting hepatic LPA mRNA. Phase II data showed 80% Lp(a) reduction at the 60 mg monthly dose 13. The Lp(a)HORIZON outcomes trial (N=8,323) is evaluating cardiovascular event reduction.
• Olpasiran (Amgen): A small interfering RNA (siRNA) that reduced Lp(a) by over 95% at higher doses in the OCEAN(a)-DOSE Phase II trial 14. Dosed every 12 weeks subcutaneously.
• Lepodisiran (Eli Lilly): Another siRNA approach that achieved near-complete Lp(a) suppression lasting 24-48 weeks after a single dose in Phase I 15.

Dr. Christie Ballantyne, Baylor College of Medicine, noted regarding these trials: "For the first time we have agents that can reduce Lp(a) by 80 to 95 percent. The outcomes trials will tell us whether that magnitude of reduction translates to event reduction, which Mendelian randomization data strongly predict."

Clinical Management When Lp(a) Is Elevated

Until targeted Lp(a) therapies gain approval, management focuses on aggressive modification of all other modifiable risk factors. The EAS recommends treating elevated Lp(a) as a reason to intensify LDL-C lowering 4.

Practical steps for patients with Lp(a) above 50 mg/dL:

1. Target LDL-C below 70 mg/dL (or below 55 mg/dL if additional risk factors are present), per 2019 ESC/EAS guidelines
2. Optimize blood pressure to below 130/80 mmHg
3. Maintain HbA1c below 7.0% if diabetic
4. Do not smoke; counsel cessation aggressively
5. Consider PCSK9 inhibitor therapy if LDL-C remains above goal on maximally tolerated statin plus ezetimibe
6. Cascade screening of first-degree relatives (50% probability of inheriting the elevated Lp(a) allele)

Lifestyle modifications (diet, exercise, weight loss) do not meaningfully lower Lp(a). This is not a failure of effort. The particle concentration is genetically fixed. Telling patients this directly reduces unnecessary guilt and misdirected interventions.

Repeat Testing: When (and When Not) to Recheck

Because Lp(a) is genetically determined and stable across decades, repeat testing is rarely indicated. The EAS explicitly states that serial monitoring adds no clinical value in most cases 4.

Exceptions where repeat measurement is reasonable:

• After initiation of PCSK9 inhibitor therapy (to quantify degree of Lp(a) reduction)
• After enrollment in a clinical trial of an Lp(a)-lowering agent
• If the initial test was performed during an acute illness, nephrotic flare, or pregnancy (all of which can transiently alter levels)
• If the initial measurement used a mass-based assay and you want to confirm with an isoform-insensitive nmol/L assay

Do not recheck Lp(a) annually. Do not recheck after dietary changes. The number will not change.

How Lp(a) Interacts With Other Lipid Markers

Lp(a) cholesterol is embedded within the standard LDL-C measurement on a basic lipid panel. This creates a clinical blind spot. A calculated "corrected LDL-C" can be estimated by subtracting 30% of the Lp(a) mass-based value from the reported LDL-C, though this approximation has limitations 3.

For example: if LDL-C is 130 mg/dL and Lp(a) is 60 mg/dL, the corrected LDL-C is approximately 130 - (0.30 × 60) = 112 mg/dL. The remaining 18 mg/dL of cholesterol attributable to Lp(a) particles represents risk that statins address poorly.

High Lp(a) combined with elevated LDL-C or low HDL-C compounds risk multiplicatively. The OxPL (oxidized phospholipids) carried on Lp(a) particles accelerate plaque formation beyond what cholesterol content alone would predict. Patients with the triad of elevated Lp(a), elevated LDL-C, and family history of premature CAD should be managed as high-risk regardless of their calculated 10-year ASCVD score.